Glycopeptide
Staphylococcus aureus (Oritavancin susceptible), Coagulase negative Staphylococci, Streptococcus pneumoniae, Streptococcus spp., Enterococcus spp. (Oritavancin susceptible), C. jeikeium, Clostridium spp. (except clostridioforme),, Actinomyces, Propionibacterium spp.,
Oritavancin inhibits the bacterial cell wall biosynthesis by binding to the C-terminal of the D-alanyl-D-alanine peptidoglycan chain
No data
Phase III studies ongoing
Studies ongoing
Not commercially available
Not yet determined
Not yet determined
Unknown
Unknown
Therapeutic: Culture and sensitivities, serum levels, signs and symptoms of infection, white blood cell count
Not currently available